MRI radiomics model for predicting tumor immune microenvironment types and efficacy of anti-PD-1/PD-L1 therapy in hepatocellular carcinoma.
Journal:
BMC medical imaging
Published Date:
Jul 1, 2025
Abstract
BACKGROUND: To improve the prediction of immune checkpoint inhibitors (ICIs) efficacy in hepatocellular carcinoma (HCC), this study categorized the tumor immune microenvironment (TIME) into two types: immune-activated (IA), characterized by a high CD8 + score and high PD-L1 combined positive score (CPS), and non-immune-activated (NIA), encompassing all other conditions. We aimed to develop an MRI-based radiomics model to predict TIME types and validate its predictive capability for ICIs efficacy in HCC patients receiving anti-PD-1/PD-L1 therapy.
Authors
Keywords
No keywords available for this article.